Bowles, Dawn E <br/><br/>
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.  [electronic resource] 

 -  Molecular therapy : the journal of the American Society of Gene Therapy  Feb 2012 
 - 443-55 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1525-0024 
<br/><br/><label>Standard No.: </label>10.1038/mt.2011.237  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amino Acid Sequence<br/>Animals<br/>Antibodies, Neutralizing--immunology<br/>Antibodies, Viral--immunology<br/>Capsid Proteins--chemistry<br/>Cell Line<br/>Child<br/>Child, Preschool<br/>Dependovirus--genetics<br/>Dystrophin--genetics<br/>Genetic Therapy<br/>Genetic Vectors--administration & dosage<br/>Humans<br/>Male<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Inbred C57BL<br/>Models, Molecular<br/>Molecular Sequence Data<br/>Muscle, Skeletal--metabolism<br/>Muscular Dystrophy, Duchenne--genetics<br/>Protein Conformation<br/>Sequence Alignment<br/>T-Lymphocytes--immunology<br/>Transduction, Genetic<br/>Viral Tropism